Biotech stocks are known for dramatic gains, and this year's top performers are helping the industry live up to its reputation. Investors excited about the future of gene therapy have seen CRISPR Therapeutics AG (NASDAQ: CRSP) more than quadruple its shareholders' money over the past year.The gene-editing stock has put up a dazzling performance, but it pales in comparison to Endocyte Inc.